ClinicalTrials.gg
RecruitingNCT06574503Updated Dec 5, 2024

Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

A Phase 3 interventional study of GP681 40mg and GP681 Simulant in Influenza, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
748
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Planned enrollment
53rd of 157
748 · median 360
Started
2024
with 16 others
Phase 3
46 of 173
9 open now
Primary completion
2027-07
later than 30 of 36 live
Registered
132nd of 173
by date
Lead sponsor
7 of 173
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Among the 173 studies in Influenza, Human with a site in China, this one is the 53rd largest by planned enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2024, is one of 46 in phase 3, reaches primary completion later than 30 of the 36 other live ones, and was the 132nd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening. Their eligible households will be randomized to either GP681 tablets or placebo if at least 1 household contacts have not received influenza vaccine with 6 months of screening and if all household contacts screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from household contacts up to Day 10, and through the assessment of symptoms.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Index patients(IPs)

  1. Male or female patients aged≥2 years at the time of signing the form.
  2. The first patient in a household with a diagnosis of influenza virus infection confirmed by all of the following in the influenza season:
  3. Positive Influenza rapid antigen test or Polymerase chain reaction (PCR), and;
  4. Fever (axillary temperature ≥37.3℃) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken.
  5. Patients with onset of fever within 48 hours or less at informed consent.
  6. Patients live in a household where all household contacts are expected to meet the key household contacts inclusion criteria (criteria 2, 3, \& 4).
  7. Patients and/or their guardian who are willing to provide written informed consent and consent to participate in the study, able to understand the study and comply with all study procedures.

Household contacts of index patients:

  1. Male or female patients aged≥12 years at the time of signing the informed consent form.
  2. Household contacts who are able to provide informed consent within 24 hours or less from informed consent in index patients.
  3. Subjects who had lived with the index patient for 3 months or more prior to informed consent.
  4. Subjects who meet all of the following criteria and are judged not to have influenza virus infection by the investigator.
  5. Negative Influenza rapid antigen test or Polymerase chain reaction (PCR), and;
  6. Subjects who have a body temperature (axillary) \< 37.3°C at Screening, and;
  7. Subjects who have no influenza like symptoms (cough, sore throat, headache, nasal discharge/nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) at Screening.
  8. Household contacts intended for full study have not received influenza vaccine within 6 months prior to screening;
  9. Subjects and/or their guardian who are willing to provide written informed consent and consent to participate in the study, able to understand the study and comply with all study procedures, including patient health diary records.

Exclusion criteria

Exclusion Criteria:

Household contacts of index patients:

  1. History of allergic reactions attributed to GP681 or any of the ingredients of its formulation.
  2. Subjects with household members other than the index patient that was diagnosed with or strongly suspected to have influenza in the past 12 weeks.
  3. subjects with concurrent bacterial or other virus infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations.
  4. Subjects who are unable to live with the index patient from Screening until Day 10.
  5. Known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, stomach after subtotal resection, etc.).
  6. Subjects who have any underlying diseases requiring systemic , treatment of antipyretics/analgesics, , or agents.
  7. Subjects with [HIV] infection.
  8. Subjects with severe (Grade 3 or higher of [CTCAE] ver. 5) underlying diseases.
  9. Treatment with anti-influenza virus drugs (oseltamivir, zanamivir, peramivir, favipiravir, abidol, baloxavir marboxil, amantadine, or rimantadine) within 2 weeks before screening.
  10. Known history of alcohol abuse (Average weekly intake of alcohol is more than 14 units alcohol (1 units ≈ 360 mL beer, or 45 mL spirits with 40% content, or 150 mL wine) or drug abuse at screening;
  11. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or below do not need to undergo a pregnancy test at the predose examinations:

    1. women (defined as cessation of regular menstrual periods for 2 years or more and aged more than 50 years old)
    2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
  12. Has received any agents or devices for any indication within 30 days prior to Screening.
  13. Subjects who, in the opinion of the Investigator, may not be qualified or suitable for the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
748 participants (estimated)

Study arms

  • Experimental
    GP681 tablet 40mg

    atients in the GP681 tablet 40mg group will receive a single oral dose of GP681 tablet 40mg with water.

    Drug: GP681 40mg

  • Placebo comparator
    Placebo group

    Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg with water.

    Drug: GP681 Simulant

Interventions

  • 2X20mg tablets taken orally

  • DrugGP681 Simulant

    Placebo tablets matching GP681 40mg

06

What researchers measure

Primary outcomes

  1. Proportion of household members who are infected with influenza virus (Q-PCR positive), and present with fever and at least one influenza symptom with severity of moderate or severe in the period from Day 1 to Day 10.

    Defined as the proportion of household members having body temperature (axillary)≥37.3°C, having symptom of influenza (respiratory symptoms or systemic symptoms) with a severity of "2, Moderate" or "3, Severe" assessed in the subject diary, and influenza virus positive assessed by Q-PCR.

    Time frame: up to Day 10

Secondary outcomes

  1. Proportion of household members who are infected with influenza virus (Q-PCR positive), and present with fever or at least one influenza symptom with severity of moderate or severe in the period from Day 1 to Day 10.

    Defined as the proportion of household members having body temperature (axillary)≥37.3°C, or having symptom of influenza (respiratory symptoms or systemic symptoms) with a severity of "2, Moderate" or "3, Severe" assessed in the subject diary, and influenza virus positive assessed by Q-PCR.

    Time frame: up to Day10

  2. Proportion of household members with influenza virus infection in the period from Day 1 to Day 10

    Defined as the proportion of subjects having influenza virus positive assessed by RT-PCR regardless of body temperature or influenza symptoms.

    Time frame: up to Day10

  3. Time from study treatment to the time when fever, at least one influenza symptom with severity of moderate or severe, and influenza virus infection were observed.

    Defined as the later timepoint of the following (1) and (2): 1. Timepoint when body temperature (axillary) rises first to " 37.3°C 2. Timepoint when an influenza symptom was first assessed as"2, Moderate" or "3, Severe" in the subject diary. If a household member does not have a body temperature (axillary) of "37.3°C or influenza symptom was not assessed as"2, Moderate" or "3, Severe" in the period from Day 1 to Day 10, the subject will be handled as a censored case.

    Time frame: up to Day10

  4. Time from study treatment to the time when fever or at least one influenza symptom (respiratory symptom or systemic symptom), and influenza virus infection are observed.

    Defined as the timepoint of the following (1) and (2), whichever is earlier: 1. Timepoint when body temperature (axillary) rises first to " 37.3°C 2. Timepoint when an influenza symptom was first assessed as"2, Moderate" or "3, Severe" in the subject diary. If a subject does not have a body temperature (axillary) of "37.5°C and influenza symptoms (respiratory symptoms and systemic symptoms) were not assessed as 2, Moderate or 3, Severe in the period from Day 1 to Day 10, the subject will be handled as a censored case.

    Time frame: up to Day10

  5. Proportion of asymptomatic influenza-infected (Q-PCR positive) household members in the period from Day 1 to Day 10

    Defined as the proportion of household members having body temperature (axillary) \< 37.5°C, influenza symptoms all assessed as 0, Absent or 1, Mild , and influenza virus positive assessed by Q-PCR.

    Time frame: Up to Day 10

  6. Proportion of household members who are not infected with influenza virus (Q-PCR negative) and present with fever and at least one influenza symptom with severity of moderate or severe in the period from Day 1 to Day 10

    Defined as the proportion of household members having body temperature (axillary) "37.3°C, having symptom of influenza (respiratory symptoms or systemic symptoms) with a severity of "2, Moderate" or "3, Severe" assessed in the subject diary, and influenza virus negative at all time points assessed by Q-PCR.

    Time frame: Up to Day 10

  7. Proportion of household members who are infected with influenza virus (Q-PCR positive) in the period from Day 1 to Day 10, with virus subtype consistent with index patient

    Defined as the proportion of household members who are infected with influenza virus (Q-PCR positive) in the period from Day 1 to Day 10,and the virus subtype of household members are consistent with index patient

    Time frame: Up to Day 10

07

Study locations

1 of 1 sites recruiting
  • Shulan (Hang Zhou) Hospital
    Hanzhou, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 31 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Aug 28, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Jul 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06574503
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Dec 1, 2024
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Dec 5, 2024

Study contacts

Siyuan Xi
Contact
ZRYHYYGCPEC@126.com
84206250
Bin Cao, phd
Contact
caobin_ben@163.com
13911318339

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GP681

Start the discussion